Severe thrombocytopenia after trastuzumab retreatment: A case report

被引：9

作者：

Pino M.S. ^{[1
]}

Angiolini C. ^{[1
]}

Fioretto L. ^{[1
]}

机构：

[1] Department of Oncology, Oncology Unit, Florence

来源：

BMC Research Notes | / 6卷 / 1期

关键词：

Breast cancer; Thrombocytopenia; Trastuzumab;

D O I：

10.1186/1756-0500-6-400

中图分类号：

学科分类号：

摘要：

Background: Trastuzumab prolongs survival of human epidermal growth factor receptor 2-positive breast cancer patients in both the adjuvant and metastatic settings. Currently toxicity data are not available on retreatment of metastatic breast cancer patients who relapse after adjuvant trastuzumab. We report one patient with metastatic breast cancer who developed acute thrombocytopenia after trastuzumab infusion. This patient had trastuzumab treatment in the adjuvant setting. Case presentation. A 70-year-old Caucasian woman received a diagnosis of metastatic breast cancer four years after her initial diagnosis of locally advanced, hormone receptors-positive, human epidermal growth factor receptor 2-positive breast cancer. Trastuzumab retreatment was planned. Less than 24 hours after trastuzumab infusion, the patient was admitted to the hospital for the appearance of diffuse petechial hemorrhages and ecchymosis. The patient was confirmed to have a severe trastuzumab-induced thrombocytopenia. A rapid and complete recovery was observed after high-dose intravenous corticosteroids and immunoglobulin. No trastuzumab retreatment was attempted. Conclusion: Among the reported cases of trastuzumab-induced thrombocytopenia, this is the first report in the literature occurring in a patient retreated with trastuzumab after adjuvant therapy. © 2013 Pino et al.; licensee BioMed Central Ltd.

引用

共 13 条

[1]

Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E., Geyer Jr. C.E., Martino S., Mamounas E.P., Kaufman P.A., Wolmark N., Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31, J Clin Oncol, 29, pp. 3366-3373, (2011)

[2]

Gianni L., Dafni U., Gelber R.D., Azambuja E., Muehlbauer S., Goldhirsch A., Untch M., Smith I., Baselga J., Jackisch C., Cameron D., Mano M., Pedrini J.L., Veronesi A., Mendiola C., Pluzanska A., Semiglazov V., Vrdoljak E., Eckart M.J., Shen Z., Skiadopoulos G., Procter M., Pritchard K.I., Piccart-Gebhart M.J., Bell R., Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial, Lance

[3]

Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., Pinter T., Valero V., Liu M.C., Sauter G., Von Minckwitz G., Visco F., Bee V., Buyse M., Bendahmane B., Tabah-Fisch I., Lindsay M.A., Riva A., Crown J., Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, pp. 1273-1283, (2011)

[4]

Joensuu H., Bono P., Kataja V., Alanko T., Kokko R., Asola R., Utriainen T., Turpeenniemi-Hujanen T., Jyrkkio S., Moykkynen K., Helle L., Ingalsuo S., Pajunen M., Huusko M., Salminen T., Auvinen P., Leinonen H., Leinonen M., Isola J., Kellokumpu-Lehtinen P.L., Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial, J Clin Oncol, 27, pp. 5685-5692, (2009)

[5]

Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, pp. 783-792, (2001)

[6]

Baselga J., Carbonell X., Castaneda-Soto N.J., Clemens M., Green M., Harvey V., Morales S., Barton C., Ghahramani P., Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule, J Clin Oncol, 23, pp. 2162-2171, (2005)

[7]

Hudis C.A., Trastuzumab-mechanism of action and use in clinical practice, N Engl J Med, 357, pp. 39-51, (2007)

[8]

Mantzourani M., Gogas H., Katsandris A., Meletis J., Severe thrombocytopenia related to trastuzumab infusion, Med Sci Monit, 17, (2011)

[9]

Drudi F., Gianni L., Fantini M., Ravaioli A., Trastuzumab-related thrombocytopenia: Always a self-limiting complication?, Ann Oncol, 21, pp. 668-669, (2010)

[10]

Jara Sanchez C., Olier Garate C., Garcia-Donas Jimenez J., Penalver Parraga J., Drug-induced thrombocytopenia induced by trastuzumab: A special challenge in a curable disease, Ann Oncol, 20, pp. 1607-1608, (2009)

← 1 2 →